Platelet activation increases with the severity of peripheral arterial disease: Implications for clinical management

Journal of Vascular Surgery

Volumn 46, Issue 3, 2007, Pages 485-490

  Rajagopalan, Sriram ^a   Mckay, Ian ^a   Ford, Isobel ^a   Bachoo, Paul ^b   Greaves, Michael ^a   Brittenden, Julie ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; FIBRINOGEN; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMITTENT CLAUDICATION; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REST; STIMULATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ULCER;

ADULT; AGED; AGED, 80 AND OVER; ARACHIDONIC ACID; BLOOD PLATELETS; BLOOD PRESSURE; DISEASE PROGRESSION; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; PROGNOSIS; RECEPTORS, CELL SURFACE; SEVERITY OF ILLNESS INDEX;

EID: 34548498095     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.05.039     Document Type: Article

References (35)

1. Belch J.J.F., Topol E.H., Agnelli C., Bertrand M., Califf R.M., Clement D.L., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003) 884-892
2. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
3. Fowkes F.G. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg 2 (1988) 283-291
4. Dormandy J., Heeck L., and Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 12 (1999) 123-137
5. SIGN Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of peripheral artery disease-A national clinical guideline (2006). http://www.sign.ac.uk October. www.sign.ac.uk
6. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G., and TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). [Consensus Development Conference Journal Article]. J Vasc Surg 45 Suppl S (2007) S5-S67
7. Cassar K., Bachoo P., and Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 15 (2003) 6-15
8. Robless P.A., Okonko D., Lintott P., Mansfield A.O., Mikhailidis D.P., and Stansby G.P. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25 (2003) 16-22
9. Cassar K., Bachoo P., Ford I., Greaves M., and Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 38 (2003) 99-103
10. Koksch M., Zeiger F., Wittig K., Siegemund A., Reininger C.B., Pfeiffer D., et al. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 21 (2001) 147-154
11. Galt S.W., McDaniel M.D., Ault K.A., Mitchell J., and Cronenwett J.L. Flow cytometric assessment of platelet function in patients with peripheral arterial occlusive disease. J Vasc Surg 14 (1991) 747-755 discussion 755-6
12. Antithrombosis Trialists Collaboration 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 76-81
13. Leng G.C., Lee A.J., Fowkes F.G.R., Whiteman M., Dunbar J., Housley E., et al. Incidence, Natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epid 25 (1996) 1172-1181
14. Criqui M.H., Fronek A., Barrett-Connor E., Klauber M.R., Gabriel S., and Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 71 (1985) 510-515
15. Lee A.J., Price J.F., Russell M.J., Smith F.B., van Wijk M.C., and Fowkes F.G. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 110 (2004) 3075-3080
16. Abbott R.D., Petrovitch H., Rodriguez B.L., Yano K., Schatz I.J., Popper J.S., et al. Ankle-brachial blood pressure in men >70 years of age and the risk of coronary heart disease. Am J Cardiol 86 (2000) 280-284
17. Heald C.L., Lee A.J., Murray G.D., and Fowkes F.G.R. Ankle-brachial index as an independent indicator of mortality in fifteen international population cohort studies. Circulation 112 Suppl II (2005) 798
18. O'Hare A.M., Katz R., Shlipak M.G., Cushman M., and Newman A.B. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 113 (2004) 388-393
19. Wild S.H., Byrne C.D., Smith F.B., Lee A.J., and Fowkes F.G. Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care 29 (2006) 637-642
20. Zheng Z.J., Sharrett A.R., Chambless L.E., Rosamond W.D., Nieto F.J., Sheps D.S., et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 131 (1997) 115-125
21. Cassar K., Bachoo P., Ford I., Greaves M., and Brittenden J. Randomized controlled trial of the antiplatelet effects aspirin-clopidogrel combination vs aspirin alone at angioplasty. Br J Surg 92 (2005) 166-170
22. Methods in Molecular Biology 272 Platelets and Megakaryocytes Vol 1: Functional assays ISBN: 1-58829-101-4 E-ISBN: 1-59259-782-3 ISSN: 1064-3745, humanapress.com, Humana Press Inc., Totowa, NJ, 2004. Volume editors: Gibbins JM and Mahaut-Smith MP. Chapter 19: Flow-cytometric analysis of platelet-membrane glycoprotein expression and platelet activation. Chapter authors: Goodall AH and Appleby J. Pages 225-253A.
23. Smith J.W., Steinhubl S.R., Lincoff A.M., Coleman J.C., Lee T.T., Hillman R.S., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
24. Harrison P. Platelet function analysis. Blood Rev 19 (2005) 111-123
25. Wheeler G.L., Braden G.A., Steinhubl S.R., Kereiakes D.J., Kottke-Marchant K., Michelson A.D., et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 143 (2002) 602-611
26. Collins P., Ford I., Ball D., Macaulay E., Greaves M., and Brittenden J. A preliminary study on the effects of exercising to maximum walking distance on platelet and endothelial function in patients with intermittent claudication. Eur J Vasc Endovasc Surg 31 (2006) 266-273
27. Collins P., Ford I., Greaves M., Macaulay E., and Brittenden J. Surgical revascularisation in patients with severe limb ischemia induces a pro-thrombotic state. Platelets 17 (2006) 311-317
28. Hezard N., Metz D., Nazeyrollas P., Droulle C., Potron G., and Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?. Thromb Res 108 (2002) 43-47
29. Matzdorff A.C., Kuhnel G., Kemkes-Matthes B., and Voss R. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer. J Thromb Thrombolysis 12 (2001) 129-139
30. Tan K.T., Tayebjee M.H., Lynd C., Blann A.D., and Lip G.Y. Platelet microparticles and soluble P-selectin expression in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 16 (2005) 3761-3766 vol
31. Kudoh T., Sakamoto T., Miyamoto S., Matsui K., Kojima S., Sugiyama S., et al. Relation between platelet microaggregates and ankle brachial index in patients with peripheral arterial disease. Thromb Res 117 (2006) 263-269
32. A randomised, blinded, trial of clopidogrel vs aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
33. Jagroop I.A., Matsagas M.I., Geroulakos G., and Mikhailidis D.P. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 15 (2004) 117-125
34. Klinkhardt U., Bauersachs R., Adams J., Graff J., Lindhoff-Last E., and Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 73 (2003) 232-241
35. Jones L., Griffin S., Palmer S., Main C., Orton V., Sculpher M., et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 8 (2004) 1-196